ScripAstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripIdiopathic pulmonary fibrosis (IPF) has proved to be a tough disease to crack, as last year’s trial failures from Galecto Inc. and FibroGen, Inc. have shown. But Boehringer Ingelheim GmbH has de
ScripSweden's Vicore Pharma can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid. The French drugmaker has committed to s